Pantherna Therapeutics GmbH

Pantherna Therapeutics GmbH focuses on developing innovative lipid nanoparticle technologies for targeted mRNA therapy delivery, aiming to enhance therapeutic efficacy in various clinical applications. Founded in 2014 in Germany, Pantherna Therapeutics GmbH specializes in advanced lipid nanoparticle technology for organ-specific and cell-selective delivery of mRNA-based therapeutics. The company has conducted 2 deals to date, with its most recent funding round, a Series B, raising EUR 4 million on January 3, 2022, co-led by High-Tech Gründerfonds and Riesner Verwaltungs GmbH. The CEO, Klaus Giese, leads the company as it strives to advance its innovative therapeutic approaches.

The total amount raised by the firm is EUR 4 million, with a current company valuation of EUR 18. 823 million. Pantherna Therapeutics specializes in advanced lipid nanoparticle (LNP) technologies designed for the organ-specific and cell-selective delivery of mRNA-based therapeutics. Their core product offerings, PTXmRNA™ and PTXΔLNP™, enable robust expression of therapeutic proteins targeted to specific tissues, particularly in clinical settings aimed at maximizing therapeutic impact.

These innovations target conditions such as pulmonary edema, where restoring endothelial cell function in the lungs is crucial for stabilizing vascular barriers. Pantherna’s technologies are tailored for pharmacological precision, making them applicable in diverse therapeutic areas. Their products are currently being developed for markets in Europe and potentially North America, catering primarily to pharmaceutical and biotech companies seeking innovative delivery systems for mRNA therapies. The revenue model for Pantherna Therapeutics is primarily based on partnerships and collaborations with pharmaceutical and biotech companies, focusing on pre-clinical and clinical development stages.

The company engages in B2B transactions, generating revenue through collaborative agreements that could involve licensing their proprietary technologies or co-developing mRNA therapies. Specific pricing plans for their flagship products, PTXmRNA™ and PTXΔLNP™, are not publicly available, but their partnership structures typically include milestones and deliverables aligning with the research and commercialization phases of therapeutic development. Pantherna’s ongoing collaborations and public funding from programs like the EU’s EFRE further support their operational and development costs, facilitating the growth of their therapeutic offerings in the market. In January 2022, Pantherna Therapeutics GmbH raised EUR 4 million in a venture funding round to accelerate preclinical development activities for its lead program, PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).

The company aims to enhance its product pipeline by advancing this critical program and is also targeting new markets for expansion, particularly in Europe and North America, by the end of 2023. The recent funding will be pivotal in supporting these initiatives and furthering the development of their innovative mRNA delivery technologies.